Dynamic Contrast-enhanced Area-detector CT Vs Dynamic Contrast-enhanced Perfusion MRI Vs FDG-PET/CT: Comparison of Utility for Quantitative Therapeutic Outcome Prediction for NSCLC Patients Undergoing Chemoradiotherapy

Overview

Journal Magn Reson Med Sci

Specialty Radiology

Date 2019 Mar 19

PMID 30880291

Citations 3

Authors

Shinichiro Seki

Yasuko Fujisawa

Masao Yui

Yuji Kishida

Hisanobu Koyama

Shigeharu Ohyu

Naoki Sugihara

Takeshi Yoshikawa

Yoshiharu Ohno

Affiliations

Soon will be listed here.

Abstract

Purpose: To directly compare the utility for therapeutic outcome prediction of dynamic first-pass contrast-enhanced (CE)-perfusion area-detector computed tomography (ADCT), MR imaging assessed with the same mathematical method and 2-[fluorine-18]-fluoro-2-deoxy-d-glucose-positron emission tomography combined with CT (PET/CT) for non-small cell lung cancer (NSCLC) patients treated with chemoradiotherapy.

Materials And Methods: Forty-three consecutive stage IIIB NSCLC patients, consisting of 25 males (mean age ± standard deviation: 66.6 ± 8.7 years) and 18 females (66.4 ± 8.2 years) underwent PET/CT, dynamic CE-perfusion ADCT and MR imaging, chemoradiotherapy, and follow-up examination. In each patient, total, pulmonary arterial, and systemic arterial perfusions were calculated from both perfusion data and SUV on PET/CT, assessed for each targeted lesion, and averaged to determine final values. Receiver operating characteristics analyses were performed to compare the utility for distinguishing responders from non-responders using Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria. Overall survival (OS) assessed with each index were compared between two groups by means of the Kaplan-Meier method followed by the log-rank test.

Results: Area under the curve (Az) for total perfusion on ADCT was significantly larger than that of pulmonary arterial perfusion (P < 0.05). Az of total perfusion on MR imaging was significantly larger than that of pulmonary arterial perfusion (P < 0.05). Mean OS of responder and non-responder groups were significantly different for total and systemic arterial (P < 0.05) perfusion.

Conclusion: Dynamic first-pass CE-perfusion ADCT and MR imaging as well as PET/CT are useful for early prediction of treatment response by NSCLC patients treated with chemoradiotherapy.

Citing Articles

Harnessing the Power of Radiotherapy for Lung Cancer: A Narrative Review of the Evolving Role of Magnetic Resonance Imaging Guidance.

Cheng S, Lee S, Lee H Cancers (Basel). 2024; 16(15).

PMID: 39123438 PMC: 11311467. DOI: 10.3390/cancers16152710.

Area-Detector Computed Tomography for Pulmonary Functional Imaging.

Ohno Y, Ozawa Y, Nagata H, Bando S, Cong S, Takahashi T Diagnostics (Basel). 2023; 13(15).

PMID: 37568881 PMC: 10416899. DOI: 10.3390/diagnostics13152518.

Predictive Radiomic Models for the Chemotherapy Response in Non-Small-Cell Lung Cancer based on Computerized-Tomography Images.

Chang R, Qi S, Yue Y, Zhang X, Song J, Qian W Front Oncol. 2021; 11:646190.

PMID: 34307127 PMC: 8293296. DOI: 10.3389/fonc.2021.646190.

References

Bland J, Altman D . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476):307-10. View

Manus M, Hicks R, Everitt S . Role of PET-CT in the optimization of thoracic radiotherapy. J Thorac Oncol. 2007; 1(1):81-4. View

Ohno Y, Fujisawa Y, Koyama H, Kishida Y, Seki S, Sugihara N . Dynamic contrast-enhanced perfusion area-detector CT assessed with various mathematical models: Its capability for therapeutic outcome prediction for non-small cell lung cancer patients with chemoradiotherapy as compared with that of FDG-PET/CT. Eur J Radiol. 2016; 86:83-91. DOI: 10.1016/j.ejrad.2016.11.008. View

Ohno Y, Koyama H, Yoshikawa T, Matsumoto K, Aoyama N, Onishi Y . Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. AJR Am J Roentgenol. 2011; 198(1):75-82. DOI: 10.2214/AJR.11.6525. View

Ng Q, Goh V, Milner J, Sundin J, Wellsted D, Saunders M . Quantitative helical dynamic contrast enhanced computed tomography assessment of the spatial variation in whole tumour blood volume with radiotherapy in lung cancer. Lung Cancer. 2009; 69(1):71-6. DOI: 10.1016/j.lungcan.2009.09.002. View

Hwang S, Yoo M, Park C, Jeon T, Kim S, Kim T . Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy. Eur Radiol. 2013; 23(6):1573-81. DOI: 10.1007/s00330-012-2755-0. View

Ohno Y, Koyama H, Fujisawa Y, Yoshikawa T, Seki S, Sugihara N . Dynamic contrast-enhanced perfusion area detector CT for non-small cell lung cancer patients: Influence of mathematical models on early prediction capabilities for treatment response and recurrence after chemoradiotherapy. Eur J Radiol. 2016; 85(1):176-186. DOI: 10.1016/j.ejrad.2015.11.009. View

Ohno Y, Nogami M, Higashino T, Takenaka D, Matsumoto S, Hatabu H . Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy. J Magn Reson Imaging. 2005; 21(6):775-83. DOI: 10.1002/jmri.20297. View

Ohno Y, Nishio M, Koyama H, Miura S, Yoshikawa T, Matsumoto S . Dynamic contrast-enhanced CT and MRI for pulmonary nodule assessment. AJR Am J Roentgenol. 2014; 202(3):515-29. DOI: 10.2214/AJR.13.11888. View

10.

Tacelli N, Santangelo T, Scherpereel A, Duhamel A, Deken V, Klotz E . Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. Eur Radiol. 2013; 23(8):2127-36. DOI: 10.1007/s00330-013-2821-2. View

11.

Nishino M, Hatabu H, Johnson B, McLoud T . State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology. 2014; 271(1):6-27. PMC: 4263630. DOI: 10.1148/radiol.14122524. View

12.

Yabuuchi H, Hatakenaka M, Takayama K, Matsuo Y, Sunami S, Kamitani T . Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Radiology. 2011; 261(2):598-604. DOI: 10.1148/radiol.11101503. View

13.

Sudarski S, Shi J, Schmid-Bindert G, Manegold C, Pilz L, Zhou C . Dynamic volume perfusion computed tomography parameters versus RECIST for the prediction of outcome in lung cancer patients treated with conventional chemotherapy. J Thorac Oncol. 2014; 10(1):164-71. DOI: 10.1097/JTO.0000000000000376. View

14.

Fraioli F, Anzidei M, Zaccagna F, Mennini M, Serra G, Gori B . Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology. 2011; 259(2):574-82. DOI: 10.1148/radiol.11100600. View

15.

Ohno Y, Koyama H, Yoshikawa T, Nishio M, Matsumoto S, Matsumoto K . Contrast-enhanced multidetector-row computed tomography vs. Time-resolved magnetic resonance angiography vs. contrast-enhanced perfusion MRI: assessment of treatment response by patients with inoperable chronic thromboembolic pulmonary hypertension. J Magn Reson Imaging. 2012; 36(3):612-23. DOI: 10.1002/jmri.23680. View

16.

Wang J, Wu N, Cham M, Song Y . Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol. 2009; 193(4):1090-6. DOI: 10.2214/AJR.08.1367. View

17.

Ohno Y, Hatabu H, Murase K, Higashino T, Kawamitsu H, Watanabe H . Quantitative assessment of regional pulmonary perfusion in the entire lung using three-dimensional ultrafast dynamic contrast-enhanced magnetic resonance imaging: Preliminary experience in 40 subjects. J Magn Reson Imaging. 2004; 20(3):353-65. DOI: 10.1002/jmri.20137. View

18.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

19.

Mac Manus M, Hicks R, Matthews J, McKenzie A, Rischin D, Salminen E . Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003; 21(7):1285-92. DOI: 10.1200/JCO.2003.07.054. View

20.

Bland J, Altman D . Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet. 1995; 346(8982):1085-7. DOI: 10.1016/s0140-6736(95)91748-9. View